MTNB Matinas BioPharma: Business Value

matinasbiopharma.com - graphic logo of issuer MTNB

The visualization of Matinas BioPharma (MTNB) market value, which reached 1.00, is based on the success of the LNC delivery system, which reduces drug toxicity, and expectations surrounding oral amphotericin B trials. High authority within the scientific community sustains shareholder interest in clinical trials. Looking ahead, Matinas BioPharma (MTNB) plans global expansion by scaling the licensing of its software to capture new market segments.

MTNB (Matinas BioPharma Holdings, Inc.) Total Company Value history from 11/23/2025 to 10/28/2026

Matinas BioPharma Holdings (MTNB) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Matinas BioPharma Holdings, Inc.|MTNB - Price Target Chart
- market capitalization data:
Market Capitalization Matinas BioPharma|MTNB - Enterprise Value
- book capitalization data:
Net Assets per Single Share Matinas BioPharma|MTNB - Company Book Value|Market Capitalization to Net Assets matinasbiopharma.com|MTNB - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Matinas BioPharma|MTNB - Long-Term Debt to Capital|Short-Term Debt to Capital Matinas BioPharma Holdings, Inc.|MTNB - Company Debts|Debt to Net Assets Ratio Matinas BioPharma|MTNB - Company Long-Term Debt|Company Current Liabilities Matinas BioPharma
Comprehensive company analysis:Matinas BioPharma (MTNB)
Original product of Matinas BioPharma Holdings

Assessing the financial stability of Matinas BioPharma (MTNB) requires an analysis of the enterprise value, which combines market capitalization and net debt. Historical EV trends reflect the actual cost of acquiring the company, confirming the efficiency of capital management during the development of the LNC platform and the protection of intellectual property, allowing investors to distinguish the asset's fundamental value from temporary market fluctuations.

Competitor analysis for Matinas BioPharma

Ascendis Pharma AS - Aggregate Business Value|Madrigal Pharma (MDGL) - Total Company Value|CORT - Business Value|Rhythm Pharmaceuticals (RYTM) - Enterprise Value|AKRO (akerotx.com) - Total Company Value|Total Company Value Metsera MTSR|Full Business Value MoonLake Immunotherapeutics AG|Crinetics Pharma (CRNX) - Enterprise Value|Value Adjusted for Debt and Cash NewAmsterdam Pharma Corp (NAMS)|Enterprise Value SLNO (Soleno Therapeutics)|amicusrx.com - Enterprise Value|Total Company Value 89bio (ETNB)|AGIO: Value Adjusted for Debt and Cash|GPCR (Structure Pharma) - Total Company Value|MiMedx Corp (MDXG) - Real Price to Acquire Entire Company|RZLT (Rezolute, Inc.) - Enterprise Value|Enterprise Value lexpharma.com (LXRX)|MBX Biosciences (MBX) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Total Company Value|Real Price to Acquire Entire Company Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Enterprise Value|biomeafusion.com (BMEA) - Total Enterprise Value|QNCX - Real Price to Acquire Entire Company|Fractyl Health Inc. (GUTS) - Aggregate Business Value|VTVT (vTv Therapeutics, Inc.) - Enterprise Value|Enterprise Value Agape ATP Corp.|Enterprise Value Pluri Inc. (PLUR)|Total Company Value SYBX (synlogictx.com)|LPCN: Total Company Value|sprucebiosciences.com - Total Enterprise Value|GLTO - Total Company Value|CTCX - Total Company Value|Lumos Pharma, Inc. - Enterprise Value|ONVO (organovo.com) - Company Buyout Price|RDUS: Total Company Value